With the participation of five cancer centers and clinics, Taproot is hoping to build a national, prospective data registry that is much needed but has been difficult to advance to date.
Contextual Genomics' recently launched assay screens for cell-free circulating tumor DNA in plasma to identify somatic genome alterations.
The firm cited continued delays in getting instruments set up and running in labs, leading to less generation of consumables revenues.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
The company said it anticipates $19.2 million in revenues for full-year 2019, which would miss the consensus Wall Street estimate of $19.4 million.
The company recently changed its name from Interpace Diagnostics as it expands its focus to include drug discovery and development services.
Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.
Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.
The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.
The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.
The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019.
The Church Lab spinout has now raised more than $50 million to develop and commercialize its fluorescent in situ sequencing technology for spatial genomics.
Quidel said that it expects fourth quarter 2019 revenues to be in the range of $151 million to $152 million, which would eclipse analyst expectations.
The firm also announced an exclusive distribution deal covering Israel for its T2 Resistance, T2Bacteria, and T2Candida panels
The company said it delivered 4,480 DecisionDx-Melanoma test reports in Q4 2019 compared to 3,270 reports in Q4 2018.
To market its analyte specific reagents, syndromic enteric panels, and other tests, the firm is building a US-based sales organization.
A genome-wide association meta-analysis involving almost one million heart failure cases and controls identified 11 risk loci and helped distinguish potential causal contributors.
The clinical study will evaluate a next-generation sequencing-based test, which has the potential to detect all known respiratory pathogens in 12 hours.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.